- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00601679
Improvement of Patients With Chronic Heart Failure Using NT-proBNP (EXIMPROVECHF)
Improvement in Clinical Outcomes of Patients With Chronic Heart Failure Using Serial NT-proBNP Monitoring: The EX-IMPROVE-CHF Study
This will be a multicentre Phase IV study in which patients with chronic HF who are managed and followed by HF/heart functions clinics will be followed over a period of two years.
Clinic patients who are recruited into the study will have obligatory blood sampling for the surveillance measurement of NT-proBNP level every three months for a minimum of one year (4 samples). One-half of the subjects in each clinic will be randomized to have these NT-proBNP values made known to the attending clinic physicians and nurses, the other half will have these values blinded. During the study, attending clinic physicians can order open-label NT-proBNP or BNP assays, if available in their institution, to assist the management of their patients if they feel it is clinically needed.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Once an eligible clinic patient is identified, written informed consent will be obtained. All patients will have blood drawn for the measurement of NT-proBNP immediately after consent is obtained. The patient will then be randomized to either the usual care or NT-proBNP arm.
For each patient enrolled into the study the attending physician will ensure obligatory blood sampling for the measurement of NT-proBNP level every three months for a minimum of one year (4 samples). Conventional measures used in programmed management settings including history taking, physical and radiographic examination and echocardiography will also be undertaken as per clinical practice. Patients from both arms will be treated with the same conventional measures.
One-half of the subjects in each clinic will be randomized to have these NT-proBNP values made known to the attending clinic physicians and nurse practitioners. The other half (Usual Care) will have these values blinded. During the study, attending clinic physicians can order NT-proBNP or BNP assays, if available in their institution, to assist the management of their patients if they feel it is clinically needed. Demographic variables such as age, gender, BMI, serum creatinine, and eGFR will also be collected in both arms. A dedicated research coordinator based in St. Michael's Hospital, the core centre, will monitor patients, data and blood sample collection from all participating clinics. NT-proBNP will be measured on site in clinics with the facility to measure NT-proBNP. For clinics that do not have the facility, the samples will be shipped to the core centre for measurement and the results will be provided to the clinic within one week for those patients who are randomized to open-label NT-proBNP. The research coordinator, via close communications with the clinic nurses and physicians, will ensure the process is immaculately executed and blinding is maintained.
All patients will be followed every three months for a minimum of one year (4 samples) and will include an initial evaluation (Visit 1) along with four follow-up visits in the HF/heart functions clinics (Visits 2 - 5). A clinic visit will be requested for those patients having experienced a serious adverse event since Visit 1.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- St. Paul's Hospital
-
-
Ontario
-
Toronto, Ontario, Canada, M5B 1W8
- St Michael's Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age ≥ 18 years of age
- NYHA class II-IV heart failure
- Followed in a programmed heart failure (HF) management setting
Exclusion Criteria:
- Life expectancy <1 year due to causes other than HF such as advanced cancer
- Any other conditions that may render the patient ineligible according to the investigator's judgment
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: NT-proBNP
Surveillance NT-proBNP levels disclosed to physicians.
Intervention (e.g.
Diuretic management) based on NT-proBNP results.
|
knowledge of NT-proBNP results
|
Aucune intervention: Usual Care
Surveillance NT-proBNP levels blinded.
Intervention (e.g.
Diuretic management) based on clinical judgments.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Heart failure hospitalization and death
Délai: 2 years
|
2 years
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Time to hospitalization/admission to ED due to HF, total number of HF events, total number of hospitalizations for cardiovascular events, all-cause mortality, cardiovascular mortality, worsening in clinical status but not requiring hospital admission
Délai: 2 years
|
2 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Gordon W Moe, MD, FACC, Unity Health Toronto
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CAN0013
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Insuffisance cardiaque congestive
-
Benha UniversityRecrutement
-
Kasr El Aini HospitalComplété
-
Region SkaneInscription sur invitationInsuffisance cardiaque New York Heart Association (NYHA) Classe II | Insuffisance cardiaque Classe III de la New York Heart Association (NYHA)Suède
-
Riphah International UniversityRecrutement
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... et autres collaborateursPas encore de recrutementInsuffisance cardiaque, systolique | Insuffisance cardiaque avec fraction d'éjection réduite | Insuffisance cardiaque New York Heart Association Classe IV | Insuffisance cardiaque Classe III de la New York Heart AssociationPologne
-
Assiut UniversityRetiréSyndrome congestif pelvienEgypte
-
The Whiteley ClinicBauerfeindRecrutementSyndrome congestif pelvienRoyaume-Uni
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaInconnueEndométriose | Syndrome congestif pelvienItalie
-
Hospital de Clínicas Dr. Manuel QuintelaUniversity of the Republic, Uruguay; Centro Cardiovascular Universitario; Centro...InconnueMaladie veineuse | Syndrome congestif pelvien | Varices pelviennes
-
University of Kansas Medical CenterRecrutementDouleur pelvienne | Syndrome congestif pelvienÉtats-Unis
Essais cliniques sur NT-proBNP guided care
-
Mayo ClinicComplétéComplications de grossesse | Maladie cardiaque congénitaleÉtats-Unis
-
General Hospital Murska SobotaRoche Pharma AG; Slovenian Research Agency; Murska Sobota Municipiality; Community...InconnueInsuffisance cardiaqueSlovénie
-
Sohag UniversityPas encore de recrutement
-
University of ValenciaComplétéInsuffisance cardiaqueEspagne
-
Hospital Universitario Virgen de la ArrixacaJuan Cinca Cuscullola; Pablo García Pavía; Manuel Martinez Selles; Antoni Bayés... et autres collaborateursComplétéInsuffisance cardiaque | Fraction d'éjection ventriculaire gauche préservéeEspagne
-
The University of Hong KongInconnue
-
NHS Greater Glasgow and ClydeKarolinska University Hospital; University of British Columbia; Uppsala University et autres collaborateursRecrutementMaladies cardiovasculaires | Insuffisance cardiaqueÉtats-Unis, Suède, Canada, Danemark, Royaume-Uni
-
University of CataniaComplété
-
NHS Greater Glasgow and ClydeAstraZenecaRecrutementMaladies cardiovasculaires | Insuffisance cardiaque | Diabète sucré | Diabète de type 1 | Diabète de type 2Royaume-Uni
-
Washington University School of MedicineUniversity of Abuja Teaching HospitalComplétéTrouble hypertensif de la grossesseNigeria